Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lupin

Boehringer Ingelheim headquarters

Boehringer and Philogen collaborate on acute myeloid leukaemia

Hope to bring new therapies for the rare disease

Boehringer Ingelheim headquarters

Boehringer says anti-IL-23 drug beats Stelara in psoriasis trial

Interleukin-23 inhibitor outperforms Johnson & Johnson's blockbuster

- PMLiVE

Boehringer hails its ‘landmark year’ in respiratory

Marketing and sales head Allan Hillgrove on the company's recent efforts

- PMLiVE

Jardiance survival data wows diabetes conference

BoehringerIngelheim and Eli Lilly release top-line findings from landmark trial at EASD

- PMLiVE

Boehringer Ingelheim appoints Andreas Neumann as HR lead

He will also join the company's board ofmanaging directors

- PMLiVE

Boehringer Ingelheim’s John Pugh set for move to Accenture

Will take up London-based role in theconsultants' digital department

Boehringer Ingelheim headquarters

Boehringer teams up with Eureka on intracellular cancer targets

Alliance will use Eureka technology to identify antibodies recognising relevant proteins

- PMLiVE

Boehringer drug approved in EU for rare lung disease

Nintedanib is already available as cancer treatment

- PMLiVE

Boehringer partners with US universities

Will work with Yale and Vanderbilt on cancer projects

- PMLiVE

NICE recommends Pradaxa in blood clot indication

Boehringer drug backed to treat and prevent deep vein thrombosis and pulmonary embolism

- PMLiVE

ASH: Pradaxa antidote effective in key patient groups

Boehringer posts positive data on use of idarucizumab in elderly and people with kidney impairment

EU flag

Boehringer’s Vargatef approved in the EU for lung cancer

Marks company’s second oncology drug to hit market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links